High Precision RT For Soft-Tissue Sarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01389050 |
Recruitment Status
:
Active, not recruiting
First Posted
: July 7, 2011
Last Update Posted
: January 24, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Soft-Tissue Sarcoma | Radiation: Intensity-Modulated Radiotherapy Radiation: Daily Cone Beam CT | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Use of High Precision Radiotherapy in the Management of Soft-Tissue Sarcomas |
Study Start Date : | June 2011 |
Estimated Primary Completion Date : | June 2021 |
Estimated Study Completion Date : | June 2021 |

Arm | Intervention/treatment |
---|---|
No Intervention: Follow-up
Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
|
|
Experimental: Prospective |
Radiation: Intensity-Modulated Radiotherapy
Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
Other Name: Pre-operative IMRT
Radiation: Daily Cone Beam CT
Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
Other Name: daily cone-beam Computed Tomography (CT)
|
- To determine the extent of inter-fractional and intra-fractional movement of the GTV during radiotherapy treatments. [ Time Frame: 3 years ]To quantify and describe the movement of the tumor during and between radiotherapy treatments using imagings acquired during the course of radiotherapy planning and treatments.
- To assess the acute and long-term toxicity of pre-operative radiotherapy as a function of the dose given to normal tissues and its impact on patient quality of life. [ Time Frame: 10 years ]To describe the effect of radiotherapy to the patient by measuring the acute and long-term side-effects of radiation therapy.
- Describe variations in the volume and shape of the GTV over the course of the treatment and need for adaptive therapy. [ Time Frame: 3 years ]To measure and better define the response of the tumor to radiotherapy during treatments.
- Correlate the pattern of local recurrence with the dose of radiation delivered accounting for motions and volume changes of target structures. [ Time Frame: 10 years ]To determine whether there is a pattern of local relapse with the actual dose of radiation delivered to the tumor environment when tumor volumetric and positional changes are taken into account.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of sarcoma (except for GIST, Ewing's sarcoma and rhabdomyosarcoma) within the retroperitoneum. These include patients with locally recurrent disease
- Planned to receive pre-operative radiotherapy
- Will undergo a planning CT
- Karnofsky Performance Status of ≥ 70 within 28 days prior to study entry
- No systemic chemotherapy given prior to pre-operative radiotherapy
- Able to provide written, informed consent
- Women of childbearing potential and men who are sexually active must practice adequate contraception.
Exclusion Criteria:
- Tumor pathology of GIST, Ewing's sarcoma or rhabdomyosarcoma
- Metastatic disease to the retroperitoneum from a primary sarcoma not originating from the retroperitoneum
- Systemic chemotherapy given prior to pre-operative radiotherapy.
- Intent on giving chemotherapy ≤ 12 months from the completion of radiotherapy
- Inability to undergo a 4D-CT simulation
- KPS < 70
- Unable to provide informed consent
- Pregnant women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01389050
Canada, Ontario | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 |
Principal Investigator: | Charles Catton, MD | Princess Margaret Hospital, Canada |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT01389050 History of Changes |
Other Study ID Numbers: |
UHN REB 10-0854-CE |
First Posted: | July 7, 2011 Key Record Dates |
Last Update Posted: | January 24, 2018 |
Last Verified: | January 2018 |
Additional relevant MeSH terms:
Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms |